Low-Dose Ketamine Infusion for the Treatment of Multiple Sclerosis Fatigue

Fatigue, defined as a subjective feeling of lack of energy, is the most common symptom of multiple sclerosis (MS) and a major cause of disability among patients. It also does not have satisfactory treatments. This study is a single-center, phase II, randomized, double-blind, parallel-group, active-placebo-controlled trial of IV low-dose ketamine in patients with MS fatigue. So far, the study has completed all regulatory requirements and started recruiting participants in January 2023. Up to this day, we have screened19 participants, and 15 of them were eligible to participate and have received at least one infusion of the study medications. So far, nine participants have completed the study, and one participant, after completing the first period of the study, dropped out of the trial for personal reasons. We have scheduled at least six participants per month for the next two months. Because of the study team outreach and advertisement, we have been contacted by 50 people who expressed their interest in participating in this study. So, we have a large pool of potential participants for the next year, which guarantees continued recruitment for the study.